AU2008245425A1 - Methods and compositions for the treatment of cancer - Google Patents
Methods and compositions for the treatment of cancer Download PDFInfo
- Publication number
- AU2008245425A1 AU2008245425A1 AU2008245425A AU2008245425A AU2008245425A1 AU 2008245425 A1 AU2008245425 A1 AU 2008245425A1 AU 2008245425 A AU2008245425 A AU 2008245425A AU 2008245425 A AU2008245425 A AU 2008245425A AU 2008245425 A1 AU2008245425 A1 AU 2008245425A1
- Authority
- AU
- Australia
- Prior art keywords
- seq
- mesd
- oligopeptide
- lrp6
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims description 33
- 206010028980 Neoplasm Diseases 0.000 title claims description 29
- 201000011510 cancer Diseases 0.000 title claims description 25
- 238000011282 treatment Methods 0.000 title claims description 15
- 239000000203 mixture Substances 0.000 title description 3
- 101150021503 Mesd gene Proteins 0.000 claims description 163
- 101001039199 Homo sapiens Low-density lipoprotein receptor-related protein 6 Proteins 0.000 claims description 116
- 230000027455 binding Effects 0.000 claims description 97
- 108010038807 Oligopeptides Proteins 0.000 claims description 82
- 102000015636 Oligopeptides Human genes 0.000 claims description 82
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 75
- 229920001184 polypeptide Polymers 0.000 claims description 65
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 65
- 150000001413 amino acids Chemical class 0.000 claims description 46
- 239000013598 vector Substances 0.000 claims description 36
- 239000003446 ligand Substances 0.000 claims description 29
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 14
- 206010006187 Breast cancer Diseases 0.000 claims description 10
- 208000026310 Breast neoplasm Diseases 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 208000034578 Multiple myelomas Diseases 0.000 claims description 7
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 6
- 201000000849 skin cancer Diseases 0.000 claims description 6
- 101001043594 Homo sapiens Low-density lipoprotein receptor-related protein 5 Proteins 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102100021926 Low-density lipoprotein receptor-related protein 5 Human genes 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 148
- 102100040704 Low-density lipoprotein receptor-related protein 6 Human genes 0.000 description 103
- 235000001014 amino acid Nutrition 0.000 description 42
- 229940024606 amino acid Drugs 0.000 description 40
- 241000699660 Mus musculus Species 0.000 description 34
- 241000282414 Homo sapiens Species 0.000 description 29
- 102000013814 Wnt Human genes 0.000 description 28
- 108050003627 Wnt Proteins 0.000 description 28
- 102000005962 receptors Human genes 0.000 description 24
- 108020003175 receptors Proteins 0.000 description 24
- 230000015556 catabolic process Effects 0.000 description 22
- 238000006731 degradation reaction Methods 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 20
- 108010001831 LDL receptors Proteins 0.000 description 17
- 102000000853 LDL receptors Human genes 0.000 description 17
- 230000011664 signaling Effects 0.000 description 17
- 108700013515 Wnt3A Proteins 0.000 description 16
- 102000044880 Wnt3A Human genes 0.000 description 16
- 239000003636 conditioned culture medium Substances 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 230000012202 endocytosis Effects 0.000 description 14
- 102000040952 LDLR family Human genes 0.000 description 13
- 108091077228 LDLR family Proteins 0.000 description 13
- 239000002299 complementary DNA Substances 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 241000283690 Bos taurus Species 0.000 description 8
- 108060001084 Luciferase Proteins 0.000 description 8
- 239000005089 Luciferase Substances 0.000 description 8
- 108010016283 TCF Transcription Factors Proteins 0.000 description 8
- 102000000479 TCF Transcription Factors Human genes 0.000 description 8
- 210000004899 c-terminal region Anatomy 0.000 description 8
- 239000013553 cell monolayer Substances 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 description 7
- 241001529936 Murinae Species 0.000 description 7
- 230000001086 cytosolic effect Effects 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- 101100456734 Mus musculus Mesd gene Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000012131 assay buffer Substances 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 230000002950 deficient Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 101710099518 Dickkopf-related protein 1 Proteins 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- 108010006519 Molecular Chaperones Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 241000282577 Pan troglodytes Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000003042 antagnostic effect Effects 0.000 description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000005075 mammary gland Anatomy 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000864646 Homo sapiens Dickkopf-related protein 1 Proteins 0.000 description 3
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 description 3
- 101000666934 Homo sapiens Very low-density lipoprotein receptor Proteins 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 241000282405 Pongo abelii Species 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 102100039066 Very low-density lipoprotein receptor Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000004156 Wnt signaling pathway Effects 0.000 description 3
- 241000269368 Xenopus laevis Species 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 210000005220 cytoplasmic tail Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 102000043555 human LDLR Human genes 0.000 description 3
- 210000005119 human aortic smooth muscle cell Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002287 radioligand Substances 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000573637 Homo sapiens LRP chaperone MESD Proteins 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 102100026257 LRP chaperone MESD Human genes 0.000 description 2
- 102000005431 Molecular Chaperones Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000282569 Pongo Species 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 239000012721 SDS lysis buffer Substances 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000037180 bone health Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000008482 dysregulation Effects 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 102000055436 human LRP6 Human genes 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 238000003468 luciferase reporter gene assay Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000004897 n-terminal region Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- AWFYPPSBLUWMFQ-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=C2 AWFYPPSBLUWMFQ-UHFFFAOYSA-N 0.000 description 1
- 101710196038 Actin-10 Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091016585 CD44 antigen Proteins 0.000 description 1
- 241000244201 Caenorhabditis briggsae Species 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 101100156752 Caenorhabditis elegans cwn-1 gene Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 101100264065 Danio rerio wnt5b gene Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 101100373143 Drosophila melanogaster Wnt5 gene Proteins 0.000 description 1
- 241000287826 Gallus Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 description 1
- 101000984620 Homo sapiens Low-density lipoprotein receptor-related protein 1B Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- -1 LRP5 Proteins 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108010015372 Low Density Lipoprotein Receptor-Related Protein-2 Proteins 0.000 description 1
- 102100027121 Low-density lipoprotein receptor-related protein 1B Human genes 0.000 description 1
- 102100021922 Low-density lipoprotein receptor-related protein 2 Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101710118749 Protein Wnt-3a Proteins 0.000 description 1
- 102100037051 Protein Wnt-3a Human genes 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108090000054 Syndecan-2 Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 241001504501 Troglodytes Species 0.000 description 1
- 108010023795 VLDL receptor Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010047118 Wnt Receptors Proteins 0.000 description 1
- 102000006757 Wnt Receptors Human genes 0.000 description 1
- 108700020987 Wnt-1 Proteins 0.000 description 1
- 102000052547 Wnt-1 Human genes 0.000 description 1
- 102000052549 Wnt-3 Human genes 0.000 description 1
- 108700020985 Wnt-3 Proteins 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 235000021310 complex sugar Nutrition 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000055426 human LRP5 Human genes 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 238000010859 live-cell imaging Methods 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000003956 transport vesicle Anatomy 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91490207P | 2007-04-30 | 2007-04-30 | |
| US60/914,902 | 2007-04-30 | ||
| PCT/US2008/062092 WO2008134752A2 (en) | 2007-04-30 | 2008-04-30 | Methods and compositions for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2008245425A1 true AU2008245425A1 (en) | 2008-11-06 |
| AU2008245425A2 AU2008245425A2 (en) | 2010-01-07 |
Family
ID=39926323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2008245425A Abandoned AU2008245425A1 (en) | 2007-04-30 | 2008-04-30 | Methods and compositions for the treatment of cancer |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8198236B2 (enExample) |
| EP (1) | EP2150270A4 (enExample) |
| JP (1) | JP2010526090A (enExample) |
| AU (1) | AU2008245425A1 (enExample) |
| BR (1) | BRPI0810207A2 (enExample) |
| CA (1) | CA2685737A1 (enExample) |
| WO (1) | WO2008134752A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080227698A1 (en) * | 2005-11-08 | 2008-09-18 | Washington University | Oligopeptides for treatment of osteoporosis and other bone diseases and methods thereof |
| CA2759078A1 (en) * | 2009-05-07 | 2010-11-11 | Novartis Ag | Compositions and methods of use for binding molecules to dickkopf-1 or dickkopf-4 or both |
| WO2011138392A1 (en) * | 2010-05-06 | 2011-11-10 | Novartis Ag | Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies |
| US8883735B2 (en) | 2011-11-04 | 2014-11-11 | Novartis Ag | Low density lipoprotein-related protein 6 (LRP6)-half life extender constructs |
| KR101457371B1 (ko) | 2013-01-10 | 2014-11-04 | 강원대학교산학협력단 | 작은안구증-연관 전사인자 유래의 펩타이드 및 이를 포함하는 조성물 |
| WO2016116922A1 (en) | 2015-01-19 | 2016-07-28 | Rappaport Family Institute For Research In The Medical Sciences | Ubiquitin ligase kpc1 promotes processing of p105 nf-kappab1 to p50, eliciting strong tumor suppression |
| KR102073144B1 (ko) | 2018-12-13 | 2020-02-04 | 주식회사 엘베이스 | 올리고펩티드를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| CN114853847B (zh) | 2022-06-29 | 2022-09-27 | 中国农业大学 | 辣椒籽分离的寡肽ftle及其在预防或治疗癌症中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030166110A1 (en) * | 1997-09-18 | 2003-09-04 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| EP1235838A4 (en) | 1999-11-19 | 2003-09-10 | Human Genome Sciences Inc | 23 HUMAN SECRETED PROTEINS |
| US8637506B2 (en) * | 2003-09-22 | 2014-01-28 | Enzo Biochem, Inc. | Compositions and methods for bone formation and remodeling |
| EP1945240B1 (en) | 2005-09-16 | 2016-12-28 | Raptor Pharmaceutical Inc | Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof |
| US20080227698A1 (en) * | 2005-11-08 | 2008-09-18 | Washington University | Oligopeptides for treatment of osteoporosis and other bone diseases and methods thereof |
-
2008
- 2008-04-30 BR BRPI0810207-4A2A patent/BRPI0810207A2/pt not_active IP Right Cessation
- 2008-04-30 JP JP2010506618A patent/JP2010526090A/ja active Pending
- 2008-04-30 AU AU2008245425A patent/AU2008245425A1/en not_active Abandoned
- 2008-04-30 CA CA002685737A patent/CA2685737A1/en not_active Abandoned
- 2008-04-30 EP EP08747240A patent/EP2150270A4/en not_active Withdrawn
- 2008-04-30 US US12/598,240 patent/US8198236B2/en not_active Expired - Fee Related
- 2008-04-30 WO PCT/US2008/062092 patent/WO2008134752A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0810207A2 (pt) | 2014-10-14 |
| US8198236B2 (en) | 2012-06-12 |
| AU2008245425A2 (en) | 2010-01-07 |
| WO2008134752A2 (en) | 2008-11-06 |
| EP2150270A2 (en) | 2010-02-10 |
| EP2150270A4 (en) | 2011-09-28 |
| WO2008134752A3 (en) | 2008-12-24 |
| JP2010526090A (ja) | 2010-07-29 |
| US20100120685A1 (en) | 2010-05-13 |
| CA2685737A1 (en) | 2008-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2008245425A1 (en) | Methods and compositions for the treatment of cancer | |
| AU2017200612B2 (en) | Methods for treating fatty liver disease | |
| CN102482339B (zh) | 用于增加产热脂肪细胞的方法 | |
| US8293238B2 (en) | GDF3 antibodies and related methods | |
| JP5952847B2 (ja) | 成長因子と結合する融合タンパク質 | |
| EP3058986B1 (en) | Bmp-alk3 antagonists and uses for promoting bone growth | |
| JP2003525595A (ja) | 脈管形成に含まれる差動発現遺伝子、それにコードされるポリペプチド、及びそれを用いた方法 | |
| CA2331332A1 (en) | Anti-angiogenic proteins and methods of use thereof | |
| US20080226556A1 (en) | Removal promoters and inhibitor for apoptosis cells in vivo | |
| US7557083B2 (en) | Gastrokines and derived peptides including inhibitors | |
| Xu et al. | Analysis of molecular domains of epitope-tagged merlin isoforms in Cos-7 cells and primary rat Schwann cells | |
| US6759047B1 (en) | Anti-angiogenic proteins and methods of use thereof | |
| US20080227698A1 (en) | Oligopeptides for treatment of osteoporosis and other bone diseases and methods thereof | |
| AU3917200A (en) | Thrombospondin-2 and uses thereof | |
| Tao | The Molecular Mechanisms Underlying Ligand Specificity of the Insulin and IGF-I Receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 23 NOV 2009 |
|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |